NASDAQ:AUPH Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $9.37 +0.16 (+1.74%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$9.13▼$9.7050-Day Range$4.11▼$9.3752-Week Range$4.07▼$20.48Volume2.98 million shsAverage Volume4.35 million shsMarket Capitalization$1.33 billionP/E RatioN/ADividend YieldN/APrice Target$12.50 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aurinia Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.80 Rating ScoreUpside/Downside33.4% Upside$12.50 Price TargetShort InterestHealthy5.21% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.34Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.85) to ($0.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.15 out of 5 starsMedical Sector488th out of 1,055 stocksPharmaceutical Preparations Industry236th out of 519 stocks 3.4 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Aurinia Pharmaceuticals has a forecasted upside of 33.4% from its current price of $9.37.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted5.21% of the outstanding shares of Aurinia Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently decreased by 1.98%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AUPH. Previous Next 4.1 News and Social Media Coverage News SentimentAurinia Pharmaceuticals has a news sentiment score of 1.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Aurinia Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest42 people have searched for AUPH on MarketBeat in the last 30 days. This is an increase of 91% compared to the previous 30 days.MarketBeat Follows7 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 40% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Aurinia Pharmaceuticals is held by insiders.Percentage Held by Institutions40.36% of the stock of Aurinia Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.85) to ($0.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -11.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -11.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 2.54. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aurinia Pharmaceuticals (NASDAQ:AUPH) StockAurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States and internationally. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company is headquartered in Victoria, Canada.Read More Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Stock News HeadlinesJanuary 28, 2023 | americanbankingnews.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Forecasted to Post FY2027 Earnings of $1.47 Per ShareJanuary 24, 2023 | finance.yahoo.comAurinia Pharmaceuticals Announces Allowance of a New and Refined Method of Use Patent for LUPKYNIS® in the Treatment of Lupus Nephritis From the United States Patent and Trademark OfficeJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 14, 2023 | nasdaq.comBullish Two Hundred Day Moving Average Cross - AUPHJanuary 6, 2023 | finance.yahoo.comWhy Shares of Aurinia Pharmaceuticals Soared This WeekJanuary 3, 2023 | msn.comHot Stocks: RIVN hits new low; Chinese stocks rise; AUPH surges on settlement; PBR dropsJanuary 3, 2023 | finance.yahoo.comAurinia Announces LUPKYNIS® (voclosporin) Patent Challenge Settlement Reached With Sun PharmaceuticalsNovember 8, 2022 | finance.yahoo.comAurinia Pharmaceuticals Third Quarter 2022 Earnings: Beats ExpectationsJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…November 4, 2022 | finance.yahoo.comNewsflash: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Analysts Have Been Trimming Their Revenue ForecastsNovember 4, 2022 | theglobeandmail.comAurinia stock sinks to three-year low as B.C. biotech cuts sales forecast for lupus drugNovember 3, 2022 | finance.yahoo.comAurinia Reports Third Quarter and Nine Months 2022 Financial and Operational ResultsNovember 3, 2022 | finance.yahoo.comAurinia Pharmaceuticals (AUPH) Reports Q3 Loss, Tops Revenue EstimatesOctober 30, 2022 | finance.yahoo.comInsiders of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reaped rewards after their US$556k investment jumped another US$272kOctober 9, 2022 | finance.yahoo.comAurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Path To ProfitabilityOctober 6, 2022 | finance.yahoo.comAurinia Pharmaceuticals Inc. (AUPH)September 21, 2022 | finance.yahoo.com10 Stocks to Sell Now According to Orkun Kilic’s Berry Street CapitalSeptember 21, 2022 | marketwatch.comAurinia Pharmaceuticals: EC Approved Lupkynis for Active Lupus Nephritis >AUPHSeptember 5, 2022 | finance.yahoo.comAurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) market cap dropped US$71m last week; individual investors who hold 57% were hit as were institutionsAugust 31, 2022 | reuters.comAurinia Pharmaceuticals IncAugust 27, 2022 | thestreet.comAurinia Pharmaceuticals (AUPH) Stock Tumbles on Lupus Drug Trial DeathsAugust 16, 2022 | seekingalpha.comAurinia Pharmaceuticals: Updating My Revenue And Valuation ModelAugust 16, 2022 | nasdaq.comPossible bearish signals as Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) insiders disposed of US$5.0m worth of stockAugust 8, 2022 | finance.yahoo.comThose who invested in Aurinia Pharmaceuticals (NASDAQ:AUPH) three years ago are up 48%August 6, 2022 | msn.comAurinia Pharmaceuticals: Q2 Earnings InsightsAugust 4, 2022 | seekingalpha.comAurinia Pharmaceuticals Inc's (AUPH) CEO Peter Greenleaf on Q2 2022 Results - Earnings Call TranscriptAugust 4, 2022 | finance.yahoo.comWhy Aurinia Pharmaceuticals Stock Briefly Spiked TodaySee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Company Calendar Last Earnings11/03/2022Today1/28/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUPH CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Stock Price Forecast$12.50 High Stock Price Forecast$14.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+33.4%Consensus RatingModerate Buy Rating Score (0-4)2.80 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,970,000.00 Net Margins-89.50% Pretax Margin-88.18% Return on Equity-26.03% Return on Assets-22.85% Debt Debt-to-Equity RatioN/A Current Ratio11.01 Quick Ratio10.40 Sales & Book Value Annual Sales$45.60 million Price / Sales29.20 Cash FlowN/A Price / Cash FlowN/A Book Value$3.69 per share Price / Book2.54Miscellaneous Outstanding Shares142,110,000Free Float136,852,000Market Cap$1.33 billion OptionableOptionable Beta0.87 Key ExecutivesMr. Peter S. Greenleaf M.B.A. (Age 53)Pres, CEO & Director Comp: $1.24MMr. Joseph M. Miller CPA (Age 49)Chief Financial Officer Comp: $710.03kMr. Matthew Maxwell Donley M.B.A. (Age 54)Exec. VP of Operations & Strategy Comp: $730.21kMr. Stephen P. Robertson (Age 41)Exec. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer Comp: $722.4kMs. DeDe SheelVP of Investor RelationMr. Chris HaysVP of MarketingMr. Fran LynchVP of SalesMr. Michael R. Martin (Age 51)Chief Bus. Officer Ms. Sue EvansHead of Regulatory AffairsMr. Scott HabigChief Commercial OfficerMore ExecutivesKey CompetitorsLigand PharmaceuticalsNASDAQ:LGNDGeronNASDAQ:GERNBiohavenNYSE:BHVNCinCor PharmaNASDAQ:CINCZentalis PharmaceuticalsNASDAQ:ZNTLView All CompetitorsInsiders & InstitutionsDupont Capital Management CorpSold 15,972 shares on 1/26/2023Ownership: 0.004%XR Securities LLCBought 10,200 shares on 1/23/2023Ownership: 0.000%Douglas Lane & Associates LLCBought 12,200 shares on 1/17/2023Ownership: 0.009%Hennion & Walsh Asset Management Inc.Sold 136,874 shares on 1/12/2023Ownership: 0.116%Capital Investment Advisors LLCBought 10,000 shares on 1/5/2023Ownership: 0.028%View All Institutional Transactions AUPH Stock - Frequently Asked Questions Should I buy or sell Aurinia Pharmaceuticals stock right now? 5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUPH shares. View AUPH analyst ratings or view top-rated stocks. What is Aurinia Pharmaceuticals' stock price forecast for 2023? 5 analysts have issued 1-year price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price forecasts range from $11.00 to $14.00. On average, they predict the company's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 33.4% from the stock's current price. View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts. How have AUPH shares performed in 2023? Aurinia Pharmaceuticals' stock was trading at $4.32 at the beginning of the year. Since then, AUPH shares have increased by 116.9% and is now trading at $9.37. View the best growth stocks for 2023 here. When is Aurinia Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our AUPH earnings forecast. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.12. The biotechnology company earned $55.78 million during the quarter, compared to analysts' expectations of $38.11 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 26.03% and a negative net margin of 89.50%. What guidance has Aurinia Pharmaceuticals issued on next quarter's earnings? Aurinia Pharmaceuticals updated its fourth quarter 2022 earnings guidance on Friday, January, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28.40 million-$28.40 million, compared to the consensus revenue estimate of $26.97 million. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY). What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH." Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.12%), Capital Investment Advisors LLC (0.03%), Douglas Lane & Associates LLC (0.01%), XR Securities LLC (0.00%), XR Securities LLC (0.00%) and Dupont Capital Management Corp (0.00%). Insiders that own company stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aurinia Pharmaceuticals' stock price today? One share of AUPH stock can currently be purchased for approximately $9.37. How much money does Aurinia Pharmaceuticals make? Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.33 billion and generates $45.60 million in revenue each year. The biotechnology company earns $-180,970,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis. How many employees does Aurinia Pharmaceuticals have? The company employs 300 workers across the globe. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498. This page (NASDAQ:AUPH) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.